The Effect of Mixed Exercise and Metabolic Stress in Relationship to Age in Healthy Men

• Status: Completed
• Trial end date: 2014-04-01
• Target enrollment: 0
• Participant gender: Male

Summary

Aging in men reduces the amount of luteinizing hormone (LH) and testosterone (Te) secreted in each burst. Stress-associated mechanisms introduced by acute illness and chronic disease decrease LH and Te secretion further. A major unresolved issue is whether the aging process heightens the negative effects of a stressor (whether physical or metabolic) upon LH and Te secretion. This study will assess LH and Te secretion in response to a physical stressor (maximal exercise) and a common metabolic stressor (hyperglycemia) as a function of age in healthy men ages 18-80 yr.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Mayo Clinic

Criteria

Inclusion Criteria:

• Community dwelling, healthy men age 18 to 80

• Body-Mass Index (BMI) 18-30 kg/m2

• Willingness to provide written informed consent

• Physician acceptable screening ECG for participants 60 years and older

Exclusion Criteria:

• recent use of psychotropic or neuroactive drugs (within five biological half-live)

• obesity (outside weight range above)

• acute weight change (loss or gain of >2 kg in 6 weeks

• Laboratory test results not deemed physician acceptable

• triglycerides > 300

• BUN >30

• creatinine > 1.5 mg/dL

• liver functions tests twice upper limit of normal

• electrolyte abnormality

• anemia; hemoglobin < 12.0 gm/dL

• drug or alcohol abuse

• psychosis, depression, mania or severe anxiety

• acute or chronic organ-system disease

• endocrinopathy, other than primary thyroidal failure receiving replacement

• untreated osteoporosis

• nightshift work or recent transmeridian travel (exceeding 3 time zones within 7 days of admission)

• PSA > 4.0 ng/mL, History or suspicion of prostatic disease (elevated PSA,indeterminate nodule or mass, obstructive uropathy)

• History of carcinoma (excluding localized basal cell carcinoma removed or surgically treated with no recurrence

• History of thrombotic arterial disease (stroke, TIA, MI, angina) or deep vein thrombophlebitis

• History of CHF, cardiac arrhythmias, congential QT prolongation, and medications used to treat cardiac arrhythmias

• Gynecomastia > 2 cm, untreated

• Untreated gallbladder disease

• History of smoking greater than one ppd.